Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 2 boards, counting each seat separately. Longest: Taysha Gene Therapies Inc., 3 years.
Taysha Gene Therapies Inc.
Director
Lexeo Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 1, 2026 | Taysha Gene Therapies Inc. | Grant or award | +21,335 | — | — |
| Jun 2, 2025 | Taysha Gene Therapies Inc. | Grant or award | +56,623 | — | — |
| Jan 3, 2025 | Intellia Therapeutics Inc. | Open-market sale | −8,966 | $12.18 | $109,206 |
| Jan 1, 2025 | Intellia Therapeutics Inc. | Option exercise | +3,500 | — | — |
| May 29, 2024 | Taysha Gene Therapies Inc. | Grant or award | +49,220 | — | — |
| Mar 1, 2024 | Intellia Therapeutics Inc. | Grant or award | +37,966 | — | — |
| Jan 8, 2024 | Intellia Therapeutics Inc. | Open-market sale | −1,608 | $28.66 | $46,085 |
| Jan 8, 2024 | Intellia Therapeutics Inc. | Open-market sale | −667 | $29.38 | $19,596 |
| Jan 3, 2024 | Intellia Therapeutics Inc. | Open-market sale | −5,532 | $29.46 | $162,973 |
| Jan 1, 2024 | Intellia Therapeutics Inc. | Option exercise | +3,500 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.